Mr. Anido was appointed a Director of Aviragen Therapeutics in October 2015.
Mr. Anido has served as Chairman of the Board and Chief Executive Officer of Zynerba Pharmaceuticals since October 2014. Prior to joining Zynerba, Mr. Anido served as Chief Executive Officer and director of NuPathe, Inc. from 2012 through its acquisition by Teva Pharmaceuticals in 2014, during which time he led the company through FDA approval of its lead product, Zecuity, a transdermal patch for migraine. From 2006 to 2011, Mr. Anido served as Chief Executive Officer and President and as a director of Auxilium Pharmaceuticals, Inc., a specialty pharmaceutical company acquired by Endo International plc. Prior to its acquisition by AstraZeneca, Mr. Anido served as Executive Vice President, Sales and Marketing at MedImmune, Inc. and played a major role in the commercial success of Synagis(r), a monoclonal antibody for the prevention of respiratory syncytial infections in infants. Mr. Anido also served in a series of positions with increasing responsibility at Glaxo Wellcome, Inc, including Director, HIV Marketing and Vice President, Central Nervous System Marketing. He holds an M.B.A. and a B.S. in Pharmacy from West Virginia University.